Literature DB >> 22855140

BIK/NBK gene as potential marker of prognostic and therapeutic target in breast cancer patients.

Eunice López-Muñoz1, Adelina Hernández-Zarco, Normand García-Hernández, Isabel Alvarado-Cabrero, Gelasio Zarco-Espinosa, Fabio Salamanca-Gómez, Diego Arenas-Aranda.   

Abstract

PURPOSE: The purpose of this study is to determine the association between the BIK/NBK gene expression and estrogen receptor alpha expression.
MATERIALS AND METHODS: We determined the association of BIK/NBK gene expression by real time quantitative reverse transcription polymerase chain reaction and estrogen receptor alpha expression by immunohistochemistry in samples of breast cancer tissue.
RESULTS: We found a statistically significant correlation of BIK/NBK gene expression with the estrogen receptor alpha expression (ρ = 0.751, p = 0.004). For verify differences of BIK/NBK gene expression among ERα+ and ERα- breast cancer tissues, Mann-Whitney U test was performed, obtaining significant differences.
CONCLUSIONS: BIK/NBK gene expression may have important clinical implications and provide predictive, prognostic or therapeutic marker in breast cancer patients according to the estrogen receptor alpha expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855140     DOI: 10.1007/s12094-012-0845-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  51 in total

1.  Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells.

Authors:  Aparna C Ranganathan; Lin Zhang; Alejandro P Adam; Julio A Aguirre-Ghiso
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

Review 2.  Early breast cancer.

Authors:  John R Benson; Ismail Jatoi; Martin Keisch; Francisco J Esteva; Andreas Makris; V Craig Jordan
Journal:  Lancet       Date:  2009-04-25       Impact factor: 79.321

Review 3.  Stromal effects on mammary gland development and breast cancer.

Authors:  Bryony S Wiseman; Zena Werb
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

4.  Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells.

Authors:  M Kandouz; M Siromachkova; D Jacob; B Chretien Marquet; A Therwath; A Gompel
Journal:  Int J Cancer       Date:  1996-09-27       Impact factor: 7.396

Review 5.  Estrogen receptor interaction with estrogen response elements.

Authors:  C M Klinge
Journal:  Nucleic Acids Res       Date:  2001-07-15       Impact factor: 16.971

Review 6.  Mechanisms of estrogen action.

Authors:  S Nilsson; S Mäkelä; E Treuter; M Tujague; J Thomsen; G Andersson; E Enmark; K Pettersson; M Warner; J A Gustafsson
Journal:  Physiol Rev       Date:  2001-10       Impact factor: 37.312

7.  Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.

Authors:  Apinya Thiantanawat; Brian J Long; Angela M Brodie
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

Review 8.  Cell death regulation by the Bcl-2 protein family in the mitochondria.

Authors:  Yoshihide Tsujimoto
Journal:  J Cell Physiol       Date:  2003-05       Impact factor: 6.384

9.  Gene expression signature of estrogen receptor alpha status in breast cancer.

Authors:  Martín C Abba; Yuhui Hu; Hongxia Sun; Jeffrey A Drake; Sally Gaddis; Keith Baggerly; Aysegul Sahin; C Marcelo Aldaz
Journal:  BMC Genomics       Date:  2005-03-11       Impact factor: 3.969

10.  Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells.

Authors:  Véronique Bourdeau; Julie Deschênes; David Laperrière; Malika Aid; John H White; Sylvie Mader
Journal:  Nucleic Acids Res       Date:  2007-11-05       Impact factor: 16.971

View more
  3 in total

1.  Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer.

Authors:  Feng Zhao; Shengli Pan; Yan Gu; Shanyu Guo; Qiancheng Dai; Yingyan Yu; Wei Zhang
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

2.  The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer.

Authors:  Vrajesh Pandya; Darryl Glubrecht; Larissa Vos; John Hanson; Sambasivarao Damaraju; John Mackey; Judith Hugh; Ing Swie Goping
Journal:  Oncotarget       Date:  2016-05-31

3.  A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma.

Authors:  Guodong Shi; Jingjing Zhang; Zipeng Lu; Dongfang Liu; Yang Wu; Pengfei Wu; Jie Yin; Hao Yuan; Qicong Zhu; Lei Chen; Yue Fu; Yunpeng Peng; Yan Wang; Kuirong Jiang; Yi Miao
Journal:  Oncotarget       Date:  2017-12-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.